BiotechTube

AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Fabry's Disease

Conditions

Fabry's Disease

Trial Timeline

Nov 10, 2023 → Oct 25, 2024

NCT ID
NCT06019728

About AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine

AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine is a approved stage product being developed by Sanofi for Fabry's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT06019728. Target conditions include Fabry's Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06019728ApprovedCompleted

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84